Nitric oxide (NO) is a gas that has potent vasodilator properties. It can be administered via inhalation in situations where NO production is impaired and results in vasodilatation of the pulmonary capillaries. In term infants, the administration of inhaled NO, at a dose of 20 parts per million, may reduce the need for extracorporeal membrane oxygenation by reducing pulmonary vascular resistance and improving oxygenation. Inhaled NO is an approved therapy in term babies with severe hypoxemic respiratory failure. In premature infants, inhaled NO may increase bleeding time and decrease platelet aggregation resulting in an increased risk for intraventricular hemorrhage. Early administration of inhaled NO may also potentially decrease the risk for developing chronic lung disease in premature infants. However, since studies show conflicting results, inhaled NO should only be used in premature neonates following investigational review board approved protocols.
Introduction
In 1980, Furchgott 1 first reported that the smooth muscle in vessels reacts differently to acetylcholine-induced vasodilatation when vascular endothelium is present than when it is absent. Therefore, it was inferred that a factor present in the vascular endothelium was responsible for this observation. This factor was initially called endothelium-derived relaxing factor (EDRF). Endotheliumderived relaxing factor was later identified to be nitric oxide (NO), a gas with potent vasodilator properties. Nitric oxide is diffusible across cell membranes and has a high affinity to bind to hemoglobin. The diffusion of endogenous NO into the smooth muscle causes relaxation. Further studies revealed that NO is released from the vascular endothelium when L-argenine is converted to L-citruline and that the reaction is facilitated by the enzyme NO synthase (NOS). [2] [3] [4] Nitric oxide contributes to the relaxation of smooth muscle via the following mechanism. The stimulation of NOS activity increases the release of NO, which then diffuses in to the adjacent smooth muscle cell and binds to the heme moiety of cytosolic guanylate cyclase. Activation of guanylate cyclase increases the intracellular concentration of cyclic guanosine monophosphate, resulting in relaxation of the smooth muscle. 4 Once released, NO is quickly inactivated by combining with hemoglobin to produce methemoglobin and eventually forming inorganic nitrate and nitrites 5 ( Figure 1 ). In the presence of oxygen, NO is converted to nitrogen dioxide (NO 2 ) and peroxinitrites. High concentrations of NO 2 and peroxinitrites are harmful to the lung tissue. In situations where NO production is impaired or deficient, inhaled NO (iNO) (INOmax s , INO Therapeutics, Clinton, NJ, USA) can be administered through the inspiratory gas. Inhaled NO diffuses in to the pulmonary capillaries and produces vasodilatation when there is severe pulmonary vasoconstriction or hypoxemic respiratory failure without any systemic effects. Nitric oxide has a very short half-life (2 to 5 s), making it easy to administer into the lungs. 6 Early experiments in animals showed that iNO produced acute and sustained vasodilatation when given via inhalation. 7 These initial results led to pilot trials in babies showing that, when iNO was administered in severe pulmonary hypertension, an improvement in oxygenation was seen. 8 These observations subsequently led to large, randomized trials in infants with hypoxemic respiratory failure or persistent pulmonary hypertension of the newborn (PPHN). The results of these trials showed that, in a majority of the infants, iNO therapy reduced the need for extracorporeal membrane oxygenation (ECMO). The importance of this molecule in mammalian cells resulted in the awarding of the Nobel Prize for Medicine for its discovery in 1998. A brief review of these trials is described below.
Nitric oxide in term infants
Pulmonary hypertension of the newborn, a syndrome with high pulmonary vascular resistance causing right to left shunting of the blood across the ductus arteriosus or foramen ovale is associated with diverse pulmonary and cardiac disorders. Additionally, intrapulmonary right to left shunting can accentuate the hypoxemia from ventilation/perfusion inequality. 9 Extracorporeal membrane oxygenation is the only rescue treatment available for infants when conventional treatment has failed. Therapy with iNO can improve oxygenation by reducing the pulmonary vascular resistance and right to left shunting of blood, thus avoiding the need for ECMO. Inhaled NO therapy may also improve oxygenation by redirecting blood to better aerated alveoli, consequently improving ventilation/perfusion mismatch. Therefore, an echocardiogram is important when establishing a diagnosis of PPHN. The need for ECMO before availability of NO was 36 to 64% when the Oxygenation Index (OI) was 24 and 44, respectively. 10, 11 Four randomized, placebo controlled clinical trials have been published in near term babies with hypoxemic respiratory failure. All of them were designed to show a reduction in death and/or the need for ECMO in these infants.
Roberts et al. 12 enrolled term newborn infants (n ¼ 58) with PPHN and a postductal partial pressure of arterial oxygen of <55 on 1.0 fraction of inspired oxygen. Inhaled NO was administered at a starting dose of 80 parts per million (p.p.m.). Most patients showed a marked improvement in oxygenation and a reduction in iNO dose to <20 p.p.m. in 2 days. The need for ECMO was significantly reduced from 71 to 45% (P ¼ 0.02).
The Neonatal Inhaled Nitric Oxide Study Group (NINOS) 13 randomized newborn infants (n ¼ 235) that met, or almost met, ECMO criteria (OI ¼ 45) to receive 20 p.p.m. of iNO. The need for ECMO and/or death in this trial was reduced from 64 to 46%. Among the secondary outcomes, there was a greater improvement in oxygenation, OI, and alveolar/arterial gradient in the iNO group. No differences were seen in length of hospital stay, days on ventilator, and chronic lung disease. The Clinical Inhaled Nitric Oxide research group (CINRGI) 10 enrolled infants with PPHN (n ¼ 186) and showed similar results, with a reduction in need for ECMO from 57 to 31% (P<0.001). The primary end point in the previous three trials was a reduction in need for ECMO since, during these trials, ECMO was considered a standard treatment for PPHN not responding to conventional treatments.
Davidson et al. 11 conducted a randomized clinical trial looking at different doses of iNO in infants with hypoxemic respiratory failure. This trial was stopped due to slowing enrollment (n ¼ 155 vs n ¼ 320 planned), but showed a trend towards reduction in need for ECMO. This was not significant as the study was underpowered to determine the outcome. The protocol in this study required that the study gas be discontinued when infants met criteria for failure. Further data analysis showed that there was deterioration in OI when the study gas was discontinued in both responders and nonresponders to iNO therapy.
14 Therefore, NO should not be discontinued even in infants not responding before the initiation of ECMO.
The two pivotal studies, NINOS and CINRGI, resulted in FDA approval of iNO in 1999 as treatment for term or near term infants with hypoxemic respiratory failure. Since then, the introduction of NO treatment has significantly reduced the need for ECMO in these infants. From these studies, the optimal dose of iNO appears to be 20 p.p.m. At this dose methemoglobin concentration and NO 2 levels remain below acceptable levels.
Nitric oxide in premature infants
Endogenous NO plays several physiological roles in fetal pulmonary and transitional circulation at birth. Nitric oxide is released during the sheer stress at delivery, leading to pulmonary vasodilatation and the transition from fetal circulation to neonatal circulation. 15 Animal studies have shown that endothelial NO synthase (eNOS) activity increases markedly during the canalicular period in fetal sheep. 16 Further studies in fetal baboons reveal that there are several isoforms of NOS that evolve in a programmed fashion with an increase in the inducible form NOS (iNOS) activity before term gestation. These finding also correlate with an increase in the concentration of exhaled NO during the third trimester. 17 Currently, the mechanisms that regulate the NOS isoforms are poorly understood. These and other studies confirm that the fetus is well prepared in early gestation to respond to NO. However, the administration of iNO to premature infants is associated with side effects that need attention. Nitric oxide increases the bleeding time in a dose-dependent fashion 18 and has also been shown to inhibit platelet aggregation. 19 These side effects may increase the incidence of intraventricular hemorrhage (IVH) in premature babies. Early reports from small studies show an increase in the incidence of IVH in premature infants. 20 In a large, randomized, multicenter study, Kinsella et al. 21 enrolled severely ill premature newborns (n ¼ 80, gestational age (GA)<34 weeks) with a predicted mortality of 53% to receive iNO. The primary hypothesis was to determine if low dose iNO improves survival in severe respiratory distress syndrome unresponsive to conventional therapies. The results of the trial showed that iNO improved oxygenation but did not improve survival. More importantly, this study showed that there was no increase in the frequency or severity of IVH in the iNO group.
NO has been shown to play a role in inflammation by reducing the accumulation of neutrophils in the lungs. 22 Recently, NO has also been shown to maintain oxidative balance in premature babies. 23 Oxygen toxicity, barotraumas, and inflammation play a major role in the development of chronic lung disease. As NO improves oxygenation, ventilation/perfusion mismatch, and inflammation, there is potential for early administration iNO to reduce chronic lung disease in premature babies.
Schreiber et al. 24 conducted a double blinded, randomized, placebo controlled trial studying the effect iNO has during the first week of life on the incidence of chronic lung disease and death in premature infants. Premature infants (n ¼ 207, GA<34 weeks) were randomly assigned to receive iNO (10 p.p.m. on day 1 followed by 5 p.p.m. for 6 days) or placebo gas. A significant decrease was seen in the incidence of death or chronic lung disease in the iNO group (48.6 vs 63.7%, P ¼ 0.03) and in the incidence of severe IVH/ periventricular leukomalacia in the iNO group (12.4 vs 23.5%, P ¼ 0.04). To date, this is the only single center randomized trial that has shown that iNO, when given within the first few days of life to premature babies, reduces the incidence of both bronchopulmonary dysplasia (BPD) and severe IVH.
Van Meurs et al. 25 conducted a multicenter, randomized, placebo controlled trial in premature infants to determine if iNO reduces the rate of death or BPD. Premature infants (n ¼ 420, GA<34 weeks) with respiratory distress syndrome were given iNO (5 to 10 p.p.m.) or placebo gas 4 hours after receiving surfactant. Results showed that the rate of death or BPD were no different between the groups (80 vs 82%, P ¼ 0.52). A post hoc analysis suggested that the rate of death or BPD is reduced for infants with a birth weight greater than 1000 g, whereas infants less than 1000 g who are treated with iNO have a higher mortality and increased rate of severe IVH. Other nonrandomized trials have showed no benefit in premature babies. Similar studies from Europe have been inconclusive showing no significant differences in primary or secondary outcomes. These studies are difficult to interpret due to lack of blinding. A summary of all the trials in premature babies (published and ongoing) is shown in Table 1 . 21, 24, 25, [27] [28] [29] [30] Mestan et al. 26 published short-term neurodevelopmental outcome in premature babies at 2 years of age with promising results in iNO-treated group. Long-term neurodevelopmental outcomes in premature babies are not known.
As studies in premature babies have shown conflicting results, the role of iNO in preventing the development of chronic lung disease or severe IVH is still uncertain. Two studies are currently being conducted in North America. Kinsella is conducting a multicenter, blinded, randomized trial using iNO at a dose of 5 p.p.m. in extremely premature infants in the first 48 h of life. The primary end point is survival without BPD. Ballard is conducting another trial in which premature infants with established lung disease at a week of age are administered iNO. The results of these ongoing trials will further define the role of iNO in premature infants. However, until the results of these trials are available, use of iNO in premature infants should be considered investigational and only be used with established investigational review board approved protocols.
Conclusion
Inhaled NO is an approved therapy in term babies with severe hypoxemic respiratory failure. The optimal dose appears to be 20 p.p.m. The side effects at these doses appear to be minimal to none. Nitric oxide treatment in premature infants is considered investigational and should not be used other than in established investigational review board approved protocols. Two large randomized trials are on going and the results of these trials will clarify the role of iNO in premature infants. 
